Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBITDA Margin (2016 - 2026)

Cumberland Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 10.02% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 763.0% to 10.02% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.27%, a 1072.0% increase, with the full-year FY2025 number at 6.27%, up 1072.0% from a year prior.
  • EBITDA Margin hit 10.02% in Q4 2025 for Cumberland Pharmaceuticals, up from 23.7% in the prior quarter.
  • Over the last five years, EBITDA Margin for CPIX hit a ceiling of 11.03% in Q1 2025 and a floor of 66.07% in Q4 2023.
  • Historically, EBITDA Margin has averaged 17.34% across 5 years, with a median of 17.13% in 2023.
  • Biggest five-year swings in EBITDA Margin: plummeted -4110bps in 2023 and later soared 4841bps in 2024.
  • Tracing CPIX's EBITDA Margin over 5 years: stood at 52.33% in 2021, then skyrocketed by 52bps to 24.97% in 2022, then plummeted by -165bps to 66.07% in 2023, then surged by 73bps to 17.65% in 2024, then surged by 43bps to 10.02% in 2025.
  • Business Quant data shows EBITDA Margin for CPIX at 10.02% in Q4 2025, 23.7% in Q3 2025, and 6.9% in Q2 2025.